Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cardiff Oncology Inc (CRDF)

Cardiff Oncology Inc (CRDF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 104,410
  • Shares Outstanding, K 67,361
  • Annual Sales, $ 680 K
  • Annual Income, $ -45,430 K
  • EBIT $ -54 M
  • EBITDA $ -54 M
  • 60-Month Beta 1.33
  • Price/Sales 203.55
  • Price/Cash Flow N/A
  • Price/Book 2.18

Options Overview Details

View History
  • Implied Volatility 450.20% (+253.00%)
  • Historical Volatility 138.80%
  • IV Percentile 99%
  • IV Rank 92.07%
  • IV High 483.26% on 02/09/26
  • IV Low 66.07% on 08/13/25
  • Expected Move (DTE 8) 0.3400 (21.25%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 105
  • Volume Avg (30-Day) 869
  • Put/Call OI Ratio 0.07
  • Today's Open Interest 32,446
  • Open Int (30-Day) 29,287
  • Expected Range 1.2600 to 1.9400

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.18
  • Number of Estimates 6
  • High Estimate -0.16
  • Low Estimate -0.20
  • Prior Year -0.21
  • Growth Rate Est. (year over year) +14.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.4800 +8.11%
on 02/05/26
3.0800 -48.05%
on 01/12/26
-1.4800 (-48.05%)
since 01/09/26
3-Month
1.4800 +8.11%
on 02/05/26
3.3100 -51.66%
on 12/26/25
-0.6900 (-30.13%)
since 11/11/25
52-Week
1.4800 +8.11%
on 02/05/26
4.9900 -67.94%
on 02/21/25
-2.5600 (-61.54%)
since 02/11/25

Most Recent Stories

More News
Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRC

-  Onvansertib added to FOLFIRI/bev first-line standard of care regimen showed dose-dependent improvement in overall response rates and durability trends as measured by progression-free survival in patients...

CRDF : 1.6000 (+3.23%)
Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development

SAN DIEGO, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers,...

CTMX : 5.56 (+0.54%)
CRDF : 1.6000 (+3.23%)
Cardiff Oncology Announces Clinical Data from Investigator-Sponsored Trial with Onvansertib in Chronic Myelomonocytic Leukemia at ASH 2025

SAN DIEGO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers,...

CRDF : 1.6000 (+3.23%)
Cardiff Oncology to Present at Sidoti’s Year-End Virtual Investor Conference

SAN DIEGO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers,...

CRDF : 1.6000 (+3.23%)
Cardiff Oncology to Present at the Piper Sandler 37th Annual Healthcare Conference

SAN DIEGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers,...

CRDF : 1.6000 (+3.23%)
Cardiff Oncology: Q3 Earnings Snapshot

Cardiff Oncology: Q3 Earnings Snapshot

CRDF : 1.6000 (+3.23%)
Cardiff Oncology Reports Third Quarter 2025 Results and Provides Business Update

– Announced positive data from the ongoing Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer – – Expects...

CRDF : 1.6000 (+3.23%)
Cardiff Oncology to Participate in Two Upcoming Investor Conferences

SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers,...

CRDF : 1.6000 (+3.23%)
Cardiff Oncology to Participate in Two Upcoming Investor Conferences

SAN DIEGO, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers,...

CRDF : 1.6000 (+3.23%)
Cardiff Oncology to Participate in Three Upcoming Investor Conferences

SAN DIEGO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers,...

CRDF : 1.6000 (+3.23%)

Business Summary

Cardiff Oncology Inc. is a clinical-stage biotechnology company. It engages in developing treatment for cancer patients. The company's product pipeline consists of a Phase 1b/2 study of onvansertib in combination with FOLFIRI/Avastin(R) in KRAS-mutated metastatic colorectal cancer; a Phase 2 study of...

See More

Key Turning Points

3rd Resistance Point 1.7100
2nd Resistance Point 1.6600
1st Resistance Point 1.6300
Last Price 1.6000
1st Support Level 1.5500
2nd Support Level 1.5000
3rd Support Level 1.4700

See More

52-Week High 4.9900
Fibonacci 61.8% 3.6492
Fibonacci 50% 3.2350
Fibonacci 38.2% 2.8208
Last Price 1.6000
52-Week Low 1.4800

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar